AbbVie and Samsung Bioepis resolve Humira litigation

AbbVie has secured another settlement relating to litigation over Humira (adalimumab), a drug used to treat multiple types of arthritis as well as psoriasis.

Samsung Bioepis  entered into a global resolution with AbbVie on Thursday, April 5, over Samsung Bioepis’s proposed biosimilar product.

As part of the ceasefire, AbbVie will grant Samsung Bioepis a non-exclusive licence to AbbVie’s IP relating to Humira. In return, Samsung Bioepis will pay royalties once its adalimumab biosimilar product is launched.

Samsung Bioepis’s licence period will begin in the US on June 30, 2023. In most countries in the EU, the period will start on October 16, 2018.

In September last year, LSIPR  reported that AbbVie had settled its Humira patent dispute with Amgen.

Amgen’s biosimilar, Amgevita/Amjevita, is expected to launch in Europe in October next year and in January 2023 in the US.

Laura Schumacher, general counsel at AbbVie, said: “We continue to believe biosimilars will play an important role in our healthcare system, but we also believe it is important to protect our investment in innovation. This agreement accomplishes both objectives.”

Did you enjoy reading this story?  Sign up to our free daily newsletters and get stories sent like this straight to your inbox.

Join us at LSPN North America on April 26,  find out more here.